Dr. Reddy's Issues Clarification Regarding Allegations Tied To Engagement With Agora Advisory; Confirms Engagement Of Dhaval Buch From October 2020 To April 2021, Prior To Madhabi Buch's SEBI Chairpersonship; Asserts Compliance With Laws And Denies Any Preferential Treatment By SEBI
Portfolio Pulse from Benzinga Newsdesk
Dr. Reddy's Laboratories has clarified allegations regarding its engagement with Agora Advisory, confirming the engagement of Dhaval Buch from October 2020 to April 2021, before Madhabi Buch became SEBI Chairperson. The company asserts compliance with laws and denies any preferential treatment by SEBI.
September 10, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Dr. Reddy's Laboratories clarified its past engagement with Agora Advisory, asserting compliance with laws and denying preferential treatment by SEBI. This clarification may ease investor concerns about regulatory issues.
The clarification by Dr. Reddy's Laboratories regarding its engagement with Agora Advisory and the denial of preferential treatment by SEBI addresses potential regulatory concerns. This may stabilize investor sentiment, but the impact on stock price is likely neutral as no new negative information was revealed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80